Cardiorenal Safety and Efficacy of Sotagliflozin: A Stratified Meta-Analysis by Diabetes Type and Dosage
Abstract
Aims: Sotagliflozin is a novel dual sodium-glucose cotransporter inhibitor (SGLTi). At present, the comprehensive assessment of its influence on cardiorenal outcomes in diabetic patients remains inadequate.
Materials and methods: We retrieved and screened RCTs of sotagliflozin for diabetes from online databases. Primary endpoint was the expanded major adverse cardiovascular and heart failure composite endpoint, comprising cardiovascular death, heart failure hospitalisation, non-fatal myocardial infarction, and non-fatal stroke; secondary endpoint was substantial renal function decline. Pooled effect sizes were calculated as relative risk (RR) and 95% confidence interval (CI). Cochrane RoB 2.0 assessed bias risk. Subgroup, sensitivity, cumulative analyses, and publication bias tests verified result robustness.
Results: After strict screening, 11 high-quality RCT datasets (including 7 peer-reviewed full publications and 4 ClinicalTrials.gov registry records) were ultimately included. Meta-synthesis results demonstrated that sotagliflozin was associated with a reduced risk of the expanded cardiovascular composite endpoint (RR = 0.80, 95% CI [0.75, 0.88], p < 0.01). Regarding the incidence of a substantial decline in renal function, the sotagliflozin group showed a potential protective tendency, but it was not statistically significant (RR = 0.77, 95% CI [0.46, 1.27], p = 0.53). Subgroup analyses revealed that sotagliflozin maintained a highly consistent cardiovascular benefit…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.